Antigenics is a biopharmaceutical company working to develop patient-specific immunotherapeutics and treatments for cancers and infectious diseases. The company’s patient-specific cancer vaccine, Oncophage (vitespen; formerly HSPPC-96), is currently approved in Russia for the adjuvant treatment of kidney cancer patients at intermediate-risk for disease recurrence. Antigenics’ QS-21 is an immune adjuvant being evaluated by the company’s collaborative partners in approximately 15 clinical-stage vaccines of which four are in Phase 3 trials including non-small cell lung cancer, melanoma and malaria. Antigenics’ portfolio also includes two Phase 1 products: Aroplatin™, a third-generation liposomal platinum chemotherapeutic, and a therapeutic genital herpes vaccine.
Changed name to Agenus Inc from Antigenics Inc., 1/6/2011.